Dr. Benjamin Ebert is remarkable for his leadership in describing the genomic landscape of adult myelodysplastic syndrome (MDS), including identifying critical new roles for ribosomal dysfunction. His laboratory discovered the molecular basis of lenalidomide activity in MDS as well as multiple myeloma. Recent studies have identified clonal hematopoiesis and its contribution to both hematologic malignancies and cardiovascular disease. Along with human genetic studies, Dr. Ebert’s lab has made significant contributions to understanding the biological basis of the transformation of hematopoietic cells by somatic mutations. Currently, he is chair of the medical oncology department at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.